Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study

• DOI: 10.1016/j.pdpdt.2023.103545
• Publication Date: 2023-03-29T16:24:50Z
• Authors: Xiaofeng Zhang; Chen Yuan; Xuemin Xiao; Rui Yin; Hongzhao Lei; Yan Li; Shumao Zheng; Sijian Wen; Dongsheng Li; Xuejun Wang; Zhong Lu; Yunfeng Zhang; Weihui Zeng; Sijin He; Yuzhen Li; Dan Jian; Jun Yang; Hua Zhong; Dawei Han; Xiaoying Chen; Junfeng Zhou; Yantao Cai; Xi Peng; Zhiming Li; Xueying Liu; Tong Lin; Ruzhi Zhang; Guang Li; Yin Zhuang; Ling Liu; Yan Yan; Baoxi Wang
• Keywords: Port-wine stain; Clinical efficacy

Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) has been approved for port-wine stain (PWS) in China 2017. This study evaluated the efficacy and safety of Hemoporfin-PDT PWS a real life setting investigated factors that influence efficacy. A multicenter retrospective included patients with who underwent 29 hospitals across completed at least two months follow-up. The was based on patien photographs. total 1679 were included. After first second sessions Hemoporfin-PDT, 63.5 75.3% responded, respectively. response rate purple-type significantly lower than pink-type (OR: 0.71, 95% CI: 0.54–0.94, P < 0.05), there no significant difference between thick- 0.72, 0.42–1.22, > 0.05). limbs mid-face 0.35, 0.23–0.53, 0.0001), while observed peripheral part face, neck or other parts body (P male an age 3 years ≤ 6 Previous treatment history did not affect well tolerated. Patients have good tolerance to Hemoporfin-PDT.